MLN 2704

Drug Profile

MLN 2704

Alternative Names: MLN 591-DM1; MLN 591-DM1 conjugate

Latest Information Update: 20 Feb 2006

Price : $50

At a glance

  • Originator ImmunoGen; Millennium Pharmaceuticals
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 26 Jan 2006 Discontinued - Phase-I/II for Prostate cancer in USA (unspecified route)
  • 30 May 2005 Data presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO-2005) have been added to the adverse events ," />), pharmacokinetics and Cancer therapeutic trials section ," />)
  • 22 Feb 2005 Data from a media release have been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top